



Nexstim Receives NBS 5+ System Order from Hong Kong

Press release, Helsinki, 5 June 2025 at 9 AM (EEST)

Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) has received an order for an NBS System 5+ from its distributor Ampere Medical Limited (“**Ampere Medical**”) in Hong Kong. The end customer, Turtle & The Hare TMS Centre, is new to Nexstim and will use the system mainly in therapy and neuroscience research.

The NBS (Navigated Brain Stimulation) 5+ is an advanced system configuration designed to facilitate both diagnostic and therapeutic applications within a single navigated transcranial magnetic stimulation device. For diagnostic purposes, this system is FDA-approved for non-invasive, pre-surgical mapping of motor and speech cortices, providing essential information prior to neurosurgical procedures. Additionally, it holds FDA clearance for the treatment of Major Depressive Disorder (MDD) and CE mark for the management of chronic neuropathic pain.

Dr. Frank Zhu, founder and director of Ampere Medical, comments: *“We are excited to welcome this new customer to our growing nTMS user community in Asia and making Nexstim technology accessible to more patients in Hong Kong as well as the Greater Bay Area in China.”*

Mikko Karvinen, CEO of Nexstim, comments: *“We have been happy to work with Dr. Zhu and Ampere Medical for years. It is great to see a new Hong Kong clinic take our system and technology into use.”*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com